Precigen (NASDAQ:PGEN) Issues Quarterly Earnings Results

Precigen (NASDAQ:PGEN) posted its quarterly earnings data on Tuesday. The biotechnology company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.06, FiscalAI reports. The company had revenue of $54.98 million during the quarter, compared to the consensus estimate of $27.91 million. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. The business’s quarterly revenue was up 6322.7% on a year-over-year basis.

Here are the key takeaways from Precigen’s conference call:

• PAPZIMEOS revenue surged to $53.1 million in Q2 from $21.6 million in Q1, a more than 145% sequential increase that drove Precigen to quarterly net income of $20.1 million, or $0.05 per diluted share.
• Commercial adoption continued to broaden, with more than 500 patients registered through PAPZIMEOS SUPPORT, approximately 315 million covered U.S. lives, and increasing use across major medical centers and community practices. Management said the permanent J-code effective April 1 has helped institutions establish routine reimbursement and treatment workflows.
• Management highlighted a broad FDA label, favorable safety profile, and durability data showing 83% of patients remained in complete response beyond three years as of the April 30 cutoff, with some patients exceeding four years without additional RRP treatment. PAPZIMEOS also received seven-year U.S. market exclusivity through August 2032.
• Precigen expects PAPZIMEOS gross margins to stabilize in the high-80% to low-90% range after remaining pre-launch inventory is sold, while R&D spending is expected to rise as pipeline programs advance. The company said cash, investments, and collection of receivables should fund operations through cash-flow breakeven by the end of 2026.
• The company remains on track to begin a pediatric PAPZIMEOS trial this year, while its EMA marketing application is under review. PRGN-2009 continues in Phase 2 trials with pembrolizumab in HPV-related head and neck and cervical cancers, with updated head-and-neck data expected later in 2026.

Precigen Stock Down 1.2%

Shares of PGEN stock traded down $0.08 during trading hours on Tuesday, reaching $6.53. The company had a trading volume of 7,894,080 shares, compared to its average volume of 4,504,153. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82. Precigen has a twelve month low of $1.70 and a twelve month high of $6.80. The stock’s fifty day simple moving average is $5.03 and its 200 day simple moving average is $4.43. The company has a market capitalization of $2.33 billion, a P/E ratio of -5.53 and a beta of 1.00.

More Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Revenue and earnings substantially exceeded expectations. Quarterly revenue reached $55.0 million versus analyst estimates of approximately $28 million, while diluted EPS was $0.05 compared with an expected loss of $0.01. Precigen also reported $20.1 million in net income attributable to common shareholders and $22.6 million in operating profit. Precigen Reports Second Quarter 2026 Financial Results
• Positive Sentiment: PAPZIMEOS sales more than doubled sequentially. Net revenue from PAPZIMEOS was $53.1 million, reflecting growing U.S. adoption. Patient-hub enrollment exceeded 500 patients across major medical centers and community practices, suggesting broader commercial reach.
• Positive Sentiment: Management highlighted improving cash-flow prospects and regulatory protection. Precigen said its $38.7 million in cash, cash equivalents and investments, combined with PAPZIMEOS proceeds, is expected to support cash-flow break-even by year-end. The FDA also granted PAPZIMEOS seven years of market exclusivity, strengthening its competitive protection.
• Positive Sentiment: Analyst sentiment remains favorable. HC Wainwright reaffirmed its “buy” rating and $14 price target, while the reported median analyst target is $12.50—well above recent trading levels. Unusual options activity also showed a sharp increase in call buying, indicating elevated bullish speculation.
• Neutral Sentiment: Institutional positioning was mixed. In the latest quarter, 91 institutional investors increased their holdings while 65 reduced positions. Several funds made sizable additions, but Point72, FMR and other investors also cut exposure.
• Negative Sentiment: Insider selling may temper enthusiasm. Company insiders reported no purchases and 22 sales over the past six months. COO Rutul Shah sold 33,772 shares for approximately $219,500 under a pre-arranged Rule 10b5-1 plan; other executives also sold shares. Operating cash flow remained negative at $17.8 million, leaving execution and cash-flow improvement as important risks.

Insider Activity

In related news, insider Donald P. Lehr sold 29,131 shares of Precigen stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $4.36, for a total transaction of $127,011.16. Following the sale, the insider owned 755,461 shares of the company’s stock, valued at $3,293,809.96. The trade was a 3.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Helen Sabzevari sold 346,836 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the completion of the transaction, the chief executive officer directly owned 3,768,872 shares of the company’s stock, valued at approximately $22,198,656.08. The trade was a 8.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 956,500 shares of company stock valued at $5,248,371 in the last 90 days. Company insiders own 41.40% of the company’s stock.

Institutional Trading of Precigen

Hedge funds have recently made changes to their positions in the stock. Xponance LLC lifted its holdings in Precigen by 21.3% during the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,496 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of Precigen by 2,762.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 20,265 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 19,557 shares during the last quarter. CIBC Bancorp USA Inc. bought a new stake in shares of Precigen in the 3rd quarter valued at approximately $53,000. Squarepoint Ops LLC acquired a new stake in shares of Precigen during the 3rd quarter valued at approximately $75,000. Finally, BNP Paribas Financial Markets raised its position in shares of Precigen by 134.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 48,803 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 28,005 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Analyst Upgrades and Downgrades

PGEN has been the topic of several research analyst reports. Wall Street Zen cut shares of Precigen from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Citigroup reaffirmed an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Citizens Jmp lifted their price target on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Precigen in a research note on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $12.50.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.